5Portincasa P,Moschetta A,Calamita G,et al.pathobiology of cholesterol gallstone disease:from equilibrium ternary phase diagram to agents preventing cholesterol crystallization and stone formation[J].Current Drug Turgets -Immune,Endocrine&Metabolic Disorders,2003,3:67-81.
6Erpecum KJV,Venneman NG,Portincasa P,et al.Review article:agents affecting gall-bladder motility-role in treatment and prevention of gallstones[J].Aliment Pharmacol ther,2000,14:66-70.
7Tokumine F,Sunagawa T,Shiohira Y,et al.Drug-associated cholelithiasis:a case of sulindac stone formation and the incorporation of sulindac metabolites into the gallstones J.Tokmine,et al,1999,94:2285-2288.
8Bickford CL,Spencer AP.Biliary sludgc and hyperbilirubinemia associated with ceftriaxone in an adult:case report and teview of the literatute J.Pharmacotherapu,2005,25:1389-1395.
9Fernandes NF,Geller SA.Terbinafine hepatotoxicity:case report and review of the literature[J].A m J Gast roenterol,1998,93:459-460.
10Talwalkar JA,Soetikno RE,Carr2Locke DL,et al.Severe cholestasis related to itraconazole for the treatment of onychomy2cosis[J].A m J Gast roenterol,1999,94:3632-3633.
